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Summary 
Background: National immunization programs differ from country to coun-
try in their vaccination schedules and decisions regarding the implementa-
tion and funding of new vaccines. 
Objective: To assess the availability of decision tools, providing a standard-
ized basis for rational decision making on vaccine introduction. 
Methods: Systematic literature review, supplemented by hand-search of ref-
erences, further searches on institutional websites and contact with immuni-
zation experts. Comparison of key documents and discussion of relevant cri-
teria. 
Results: Five key documents providing an analytical framework or key ques-
tions aiming at rational decision making were found. A comparison of these 
documents revealed an overall similarity with some differences in the ap-
proach as well as the criteria. Burden of disease and vaccine characteristics 
play a key role in the decision making process. The cost-effectiveness analy-
sis is influenced by various factors and has several limitations. Therefore, 
the authors vary in their views on its significance. Other relevant factors also 
should be considered before vaccine introduction. These include, the immu-
nization program itself as well as its conformity with other programs, its fea-
sibility and how easily it can be evaluated. Acceptability, equity as well as 
ethical, legal and political considerations are discussed to highly differing 
extents. 
Conclusion: Assuming that the most comprehensive framework possible 
would not provide a feasible tool for decision makers, a stepwise procedure 
has been suggested. Comments, examples and caveats have been given for 
each step to provide a basis for further discussions. The observed lack of 
standardized measures, defined cut-off points and comparable weighing of 
included criteria currently hinder rational decision making. 
 
objective of paper: 
providing tool for 
rational decisions on 
new vaccinations 
5 documents analyzed: 
comparison of 
similarities and 
differences 
stepwise approach 
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Zusammenfassung 
Hintergrund: Nationale Impfpläne sowie einzelne Entscheidungen, neue 
Impfungen in Programme aufzunehmen und diese zu finanzieren unter-
scheiden sich stark.  
Studienziel: Die Erarbeitung einer Entscheidungshilfe, die als Basis für ei-
nen rationalen und standardisierten Entscheidungsprozess für die Aufnah-
me neuer Impfungen in nationale Impfprogramme dienen soll, war Ziel der 
Arbeit.  
Methode: Systematische Literatursuche, unterstützt durch Handsuche in 
Referenzen und auf institutionellen Webseiten sowie durch Kontaktauf-
nahme mit ImpfexpertInnen. Vergleich von Schlüsseldokumenten und Dis-
kussion der relevanten Kriterien. 
Ergebnisse: Fünf internationale Publikationen, die Analyseraster oder 
Schlüsselfragen für rationale Impfentscheidungen bieten, wurden identifi-
ziert. Ihr Vergleich zeigt Gemeinsamkeiten, aber auch Unterschiede sowohl 
im Zugang als auch den Entscheidungskriterien selbst und deren Gewich-
tung auf.  
b Die Analyse der Erkrankung, d.h. die Krankheitslast für Betroffene wie 
die klinische Manifestation und mögliche Ausprägungen, die Größe-
nordung und Public Health Relevanz des Gesundheitsproblems und 
ihrer Folgen,  
b die Prüfung bestehender  im Gesundheitssystem eingeführter Alterna-
tiven und deren Effekte, 
b die Eigenschaften der verfügbaren Impfstoffe wie prognostizierte Ef-
fektivität und bekannte Nebenwirkungen, Fragen der Bereitstellung, 
Lagerung, Eingliederung oder gar Kombination in bestehende Impf-
pläne, aber auch 
b die Kosten der Erkrankung durch Nutzung der Ressourcen (Hospitali-
sierung, Rehabilitation etc.)  
nehmen in allen Arbeiten eine zentrale und prioritäre Rolle im Ent-
scheidungsprozess ein.  
b Eine Kosten-Effektivitätsanalyse wird hingegen von diversen Faktoren 
beeinflusst: von den Kosten des Impfstoffes sowie des zusätzlichen 
Aufwands für das Impfprogramm einerseits, anderseits  von der realen 
Effektivität der Impfung basierend auf Durchimpfungsraten der Risi-
kopopulation, unerwarteten - die Akzeptanz beeinflussenden – Neben-
wirkungen, etc.  
Darüber hinaus fließen Kriterien wie die Finanzierbarkeit, die Umsetzbar-
keit und/oder Adaptierbarkeit einer neuen Impfung in den bestehenden 
Impfplan, die Möglichkeit der Überwachung der Immunantwort und -
dynamiken sowie Gleichheitsgrundsätze und ethische, rechtliche und politi-
sche Überlegungen ein. 
Schlussfolgerung: Zur Anwendung der Entscheidungshilfe wird ein Stu-
fenmodell vorgeschlagen. Der aufgezeigte Mangel an standardisierten Krite-
rien, klar definierten Grenzen und einer vergleichbaren Gewichtung der 
eingeschlossenen Kriterien, erschweren aber derzeit rationale Impfentschei-
dungsprozesse. Eine internationale Diskussion vor aktuellen Entscheidun-
gen unter Nachfragedruck ist notwendig und soll mit dem vorliegenden Be-
richt forciert werden. 
rationale 
Entscheidungshilfe zur 
Aufnahme neuer 
Impfungen in Impfpla¨ne 
5 Publikationen: 
Analyse von 
A¨hnlichkeiten und 
Unterschieden 
Entscheidungskriterien: 
Krankheitslast, 
Alternativen, 
prognostizierte Effekte, 
reale Annahmen, 
Kosten 
stufenweises Vorgehen 
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1 Introduction 
The national immunization programs of various countries differ in their 
vaccination schedules and decisions regarding the implementation and 
funding of new vaccines. One of the objectives of the Vaccine European New 
Integrated Collaboration Effort (VENICE) research project funded by the 
European public health action program is to encourage a rational approach 
in making decisions on vaccination policies. In one of its initial findings, 
VENICE discovered variations throughout Europe in the case of Human 
Papilloma Virus and Rotavirus vaccine recommendations1. This, in turn, 
raises questions about rational decision making processes.  
Vaccines are a potential preventive measure to support and increase the 
health status of a population. Many objectives have already been achieved. 
The ongoing development and commercialization of new vaccines which, on 
the one hand, target less severe or less widespread diseases and on the other 
hand are more expensive than commonly used vaccines, will challenge na-
tional health authorities worldwide. Whereas developing countries already 
struggle with problems involving the funding of vaccines and the extent of 
coverage of standard immunization programs, industrialized nations face 
problems involving the financing of expanded programs. From a public 
health perspective, limited financial resources should be distributed in a fair 
and effective manner that aims at achieving the best possible outcomes. 
Decisions on implementing new vaccines in national immunization pro-
grams should be unbiased, comprehensive and systematic and therefore 
based on deliberate, rational, comprehensible and evidence based criteria.   
Due to the lack of standardized national approaches, the aim of this study is 
twofold. First, it attempts to determine whether support for decisions con-
cerning rational vaccine introduction exists. Second, this study attempts to 
determine which criteria are crucial for a rational decision making process. 
This paper aims at giving decision support on the criteria for assessing new 
vaccines and at highlighting the main issues that have to be addressed before 
a decision can be made. 
 
heterogeneity of 
vaccination schedules 
 
 
leads to question of 
rational decision-
making  
new vaccines are 
targeting less severe 
diseases, but more 
costly 
 
 
public health 
perspective: fair & 
rational approach to use 
limited resources 
decisions to implement 
new vaccines: based on 
unbiased, 
comprehensive, 
systematic criteria 
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2 Methods 
The paper is based on a systematic review. The flowchart of literature selec-
tion is given in figure 2-1. 
Figure 2-1: Literature selection 
To gather information about rational vaccination policies a database search 
for relevant literature was conducted in MEDLINE, EMBASE, CCRCT, 
CDSR, DARE and HTA. Search terms and search strategy can be seen in ta-
ble 2-1.  
 
 
systematic review based 
on systematic literature 
search  
Rational Vaccination Policies - decision support 
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Table 2-1: Search terms and search strategy  
1 (vaccination and (polic$ or strateg$ or program$)).ti,ab. 
2 (immuni#ation and (polic$ or strateg$ or program$)).ti,ab. 
3 decision making.ti,ab. 
4 advisory structures.ti,ab. 
5 formali#ation.ti,ab 
6 design$.ti,ab.  
7 assess$.ti,ab. 
8 guideline$.ti,ab. 
9 national immuni#ation program$.ti,ab. 
10 nnv.ti,ab. 
11 qaly.ti,ab. 
12 (development of vaccination and (polic$ or program$ or 
strateg$)).ti,ab.  
13 1 or 2  
14 or/4-8  
15 13 and 14 
16 13 and 3  
17 11 and vaccination.ti,ab.  
18 9 or 10 or 12 or 15 or 16 or 17  
19 18 
20 limit 19 to humans  
 
 This search resulted in 325 hits. 229 results could be excluded fulfilling 
primarily exclusion criteria (table 2-2). Of the remaining 96 documents only 
one dealt with decision making on national immunization programs in gen-
eral2 (95 publications were excluded according to the secondarily exclusion 
criteria). 
Table 2-2: Exclusion criteria 
Primarily exclusion criteria Secondarily exclusion criteria 
Guidelines and other 
recommendations for vaccine 
introduction and program planning in 
developing countries  
recommendations for and studies 
performed with specific vaccines 
scientific basic research on vaccine 
development  
Published before 2000 
description of national immunization 
programs  
Full text in languages other than 
English 
other meanings of NNV  
 
Manual search proved to be much more effective: hand search for this paper 
resulted in the second core document,3. In its reference list, the third deci-
sion making tool was found4. To identify papers not indexed in the data-
bases, additional searches were conducted in Google and Google Scholar 
with search terms listed in table 2-1 and websites of relevant organizations 
were accessed (see table 2-3). Only in WHO library database search 
(http://dosei.who.int/) two additional main documents5,6 were found. Some 
public health experts or expert institutions were contacted by email or 
search terms & strategy 
exclusion criteria: 
developing countries, 
basic research,  
specific vaccines, 
national immunization 
programs 
manual search  
highly effective 
Methods 
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phone. A list of contact persons who assisted in further investigations or an-
swered specific questions on rational immunization policies is given in the 
annex (Table 7-1). 
Table 2-3: Web-search 
Organizational websites accessed 
Australian Government, 
Department of Health and Aging, 
Immunise Australia Program 
http://www.immunise.health.gov.a
u/ , 
Bundesministerium fu¨r Gesundheit, 
Familie und Jugend (Austria), 
Impfen 
http://www.bmgfj.gv.at/ 
 
Centers for Disease Control and 
Prevention (U.S.), Vaccines and 
Immunization 
http://www.cdc.gov/vaccines/ 
 
European Centre for Disease 
Prevention and Control, Vaccines& 
Immunisation  
http://ecdc.europa.eu/Health_topic
s/VI/VI.html 
European Union, Directorate 
General Health and Consumer 
Protection, Public Health 
http://ec.europa.eu/health/index_e
n.htm  
Ministry of Health New Zealand, 
Immunisation 
http://www.moh.govt.nz/immunisa
tion  
National Centre for Immunisation 
Research and Surveillance, Australia 
http://www.ncirs.usyd.edu.au/  
National Health Service (Great 
Britain) 
http://www.nhs.uk/ , 
http://www.immunisation.nhs.uk/  
Public Health Agency of Canada, 
Immunization and Vaccines 
http://www.phac-
aspc.gc.ca/im/index-eng.php  
 
Robert Koch Institut (Germany), 
Infektionsschutz, Impfen 
www.rki.de  
Swedish Institute for Infectious 
Diseases Control 
http://www.smittskyddsinstitutet.s
e/in-english/  
The Netherlands Vaccine Institute http://www.minvws.nl/en/organiza
tion/chart/diensten_en_instellingen
/NVI/  
World Health Organization 
(International, Regional Office for 
Europe and the Western Pacific 
Region, Pan American Health 
Organization ,WHO library 
database,) 
http://www.who.int/ , 
http://www.euro.who.int/ , 
http://www.wpro.who.int/ , 
http://www.paho.org/ , 
http://dosei.who.int/  
 
Based on the most comprehensive framework, a comparison of the five key 
documents was performed. All relevant criteria to be taken into considera-
tion during a decision making process on vaccine introduction were re-
viewed and compiled to propose a more comprehensive framework. 
Other relevant background literature aiming only at parts of the decision 
making process were introduced in the discussion to give explanatory exam-
ples. 
web-search: institutions 
concerned with 
immunisation  
identification of 5 key 
documents 
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3 Results  
3.1 Central Publications on rational  
immunization policy 
The following five key publications were included in the analysis (in order of 
their publication date):  
1. Stratton KR, Durch JS, Lawrence S, Editors Committee to Study Pri-
orities for Vaccine Development. Division of Health Promotion and 
Disease Prevention, Institute of Medicine (2000). Vaccines for the 21st 
Century: A Tool for Decisionmaking4  
The Institute of Medicine released reports on “New vaccine development: 
Establishing priorities” for the first time in 1985. In the first part of their 
current publication, the authors reassess the progress and advances made as 
well as the barriers encountered in vaccine development. The main objective 
of the work is to analyze the setting of priorities for 26 preventive and thera-
peutic vaccines against diseases of domestic public health importance and 
likely to be approved within the next two decades. For vaccine ranking they 
chose a cost-effectiveness approach. Reasons for choosing this method as 
well as its limitations are outlined. Examples for hypothetical vaccines are 
given. Information on how the analyses have been performed is provided in 
great detail and issues to be addressed concerning vaccine introduction are 
“operationalized”. In the 300 pages appendix results of analyses of each of 
the 26 vaccines are presented. The model used can be accessed and used free 
of charge on www.iom.edu/vaccinepriorities.   
2. Mansoor O, Shin S, Maher C and the Immunization Focus, World 
Health Organization, Regional Office for the Western Pacific (2000). 
Assessing new vaccines for national immunization programmes- A 
framework to assist decision makers5  
The authors provide a set of seven questions as suggested basis of their 
framework (Table 7-2 in the Annex). Working through these key questions 
should facilitate the decision making process by providing more detailed on-
going questions for each issue.  
The detailed Asian Vaccination Initiative assessment framework is presented 
in an Annex. It is used to assist in initial assessments on financing issues of a 
NIP/national Immunization Program. It identifies key information to facili-
tate the analysis of current costs and cost projections. It provides a step-by-
step manual on this process. Using this assessment, decision makers should 
be able to draw conclusions about the program and its priority needs.  
3. World Health Organization. Immunization, Vaccines and Biologicals 
(2005). Introduction Guideline- Adding a vaccine to a national immu-
nization programme: decision and implementation6  
By way of a flowchart (figure 7-1 in the Annex) the authors present key is-
sues that have to be considered before making decisions on the introduction 
of new vaccines. What is needed to implement the decision and monitor the 
impact are discussed separately. 
IOM 2000:  
 
tool for priority setting 
based on cost-
effectiveness 
WHO 2000:  
framework to facilitate 
decisions on the 
implementation of new 
vaccines 
WHO 2005:  
key issues to be 
addressed before 
decisions of new 
vaccines 
Rational Vaccination Policies - decision support 
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4. Erickson LJ, De Wals P, Farand L (2005). An analytical framework for 
immunization programs in Canada3 
The framework consists of 13 categories and explanatory notes are given. 
Key questions that should be considered before making decisions on vacci-
nation programs are listed (Table 7-3 in the Annex). The Appendix of this 
paper provides a complete list of all of the 58 criteria that had been grouped 
into the 13 categories. 
5. Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit 
G, de Melker HE (2006). Developing a vaccination evaluation model to 
support evidence-based decision making on national immunization 
programs2 
Relevant issues of consideration were grouped into three fields (Figure 7-2 
in the Annex), giving the input for following cost-effectiveness analyses. De-
tails that should be provided for each of the fields are listed in tables and 
further discussed.  
All publications aim at assisting in the making of decisions on vaccine in-
troduction and to strengthen national immunization programs2-6. Addition-
ally they might act as a common tool and language in analyzing and discuss-
ing  priorities for vaccine development and implementation4, be used as a 
tool for consensus building or public education3 or support vaccine manufac-
turers in vaccine development and presentation4. 
Two analytical frameworks3,4, two checklists2,5 and one list of key issues6 are 
presented in the analyzed papers. To collect and synthesize relevant infor-
mation for the development of the decision aids, questionnaires were sent to 
immunization experts3 and discussions with multidisciplinary health experts 
on immunization were arranged2. A committee to study priorities for vaccine 
development had been established. This group held meetings and work-
shops, heard presentations from NIP/National immunization program man-
agers and contacted other experts with targeted questions4.  The authors of 
two documents5,6 did not provide a description on the methods that led to 
the final approach (see table 3-1). 
All decision aids included might be used at national levels all over the world. 
One was originally designed for international use6 and therefore is the most 
general. The others were developed in different regions/ countries (western 
pacific region5, Netherlands2, Canada3, U.S.4), potentially influencing their 
transferability due to specific domestic considerations. The extensiveness 
and depth of the five key publications vary widely between 73 and up to 5004 
pages. The reference lists contain at least 145 and up to 1504 references. 
 
Erickson et al. 2005:  
categories to be 
considered 
Kimman et al. 2006:  
relevant issues & cost-
effectiveness analysis 
purpose of publications:  
to analyse &  discuss  
priorities for vaccine  
implementation 
 
prospective audience: 
policy makers 
 
design/ methods: 
framework, 
checklists, 
relevant issues 
 
 
target countries: 
industrialised 
 
 
Results 
LBI-HTA | 2008 17 
Table 3-1: Purpose and prospective clients & design/methods and target countries  
 
3.2 Synthesis – Criteria for rational 
immunization policy  
Though issues to be considered before vaccine introduction are quite similar 
at a first glance, comparison of the frameworks and checklists is difficult. 
The grouping of relevant factors varies, as does their predicted weight and 
detailed analysis. This might be explained by different development back-
grounds, methods and aims of the works.  
Ericksons framework3 has been chosen as the basis for direct comparison 
due to its comprehensive structure of the 13 categories.  To point out simi-
larities and highlight additional concerns, issues that should be taken into 
consideration during the decision making process were added by informa-
 Stratton 2000 WHO 2000 WHO 2005 Erickson 2005 Kimman 2006 
purpose to develop a model 
for prioritizing 
vaccine 
development, that 
is quantitative and 
relatively unbiased 
toward a specific 
vaccine candidate 
To support 
rational, logical and 
consistent 
decisions on new 
vaccines by 
clarifying the 
technical and 
operational issues 
through a series of 
technical questions 
to assist an 
informed decision 
making process to 
add a vaccine, to 
ensure smooth 
introduction of the 
new vaccine, to 
promote further 
strenghtening of 
the immunization 
program 
for structuring 
program report 
presentation; for 
structuring 
discussion and 
consensus building 
in expert 
committees, for 
teaching and public 
education 
to present an 
evaluation model 
in the form of a 
checklist, that 
may support 
decision making 
on a national 
immunization 
programs 
prospective 
audience 
vaccine science 
community, 
vaccine 
manufacturers, 
research and 
program 
policymakers 
policy makers country level 
decision-makers, 
national 
immunization 
program managers, 
consultants 
working on 
immunization 
decision-makers, 
public education 
 
decision-makers 
design/ methods analytical 
framework and 
quantitative model 
(and evaluation of 
26 specific vaccines 
for the U.S. health 
system) produced 
by an committee of 
the Institute of 
Medicine on behalf 
of the National 
Institutes of 
Health; 
checklist, methods 
not described 
list of key issues to 
be considered 
before deciding to 
introduce a 
vaccine, criteria for 
assessing the NIP 
readiness for new 
vaccine 
introduction; 
giving examples; 
methods not 
described 
analytical 
framework (58 
different criteria, 
grouped into 13 
categories) based 
on questionnaire 
sent to key 
scientific and public 
health experts 
involved in the 
planning of 
immunization 
programs across 
Canada 
checklist 
assembled after 
discussions by a 
multidisciplinary 
team consisting 
of 
microbiologists, 
immunologists, 
epidemiologists, 
experts on 
vaccine safety 
and health 
economists; 
information 
assigned to one 
of the three 
fields (vaccine, 
disease, 
pathogen) 
target countries domestic US (focus 
on conditions of 
domestic public 
health 
importance); 
special analysis of 
vaccines that could 
be developed 
within the next 
two decades, 
including 
therapeutic 
vaccines) 
international: 
Focus on Western 
Pacific countries 
international domestic (Canada) International? 
(Europe?) 
criteria to consider 
quite similar, but 
weight & relevancy 
assigned to criteria 
varying 
basis for synthesis here: 
Erickson 2005 
framework 
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tion provided by the other publications2,4-6, assigning them to these 13 cate-
gories. 
Burden of disease 
All authors agree that the burden of disease is the main or one of the most 
crucial concerns driving vaccine development and vaccine introduction. 
While there is agreement on the weight given to burden of disease, the 
analysis of details varies: 
b Infective Agent3: the characteristics of the infective agent can be de-
scribed by their pathogenicity, transmission properties and anti-
genic variation2 (table 3-2). 
Table 3-2: Pathogen issues 
Pathogenicity Transmission 
properties 
Antigenic variation 
part of population in 
contact with 
pathogen, incidence in 
(sub-) population(s), 
infectiveness during 
various stages of 
infection 
occurrence of 
variation 
variations in 
pathogenicity, 
interactions with other 
pathogens, ecological 
consequences after 
vaccine 
implementation 
(ecological niche?) 
routes of transmission, 
importance of 
different transmission 
routes 
evolutionary pressure 
leading to emergence 
of antigenic or 
virulence variants- 
consequences on 
vaccine’s effectiveness 
 
b Clinical Manifestations3  can be characterized by symptomatic or 
asymptomatic infections or carrier ship2. Designing additional 
morbidity scenarios4 requires information about typical patterns of 
disease as well as information about variations in disease presenta-
tion, patterns or severity. The duration of each phase as well as the 
proportion of infected people who will experience each pattern 
must be considered. The consequences of infection4 can be outlined 
through complications, case fatality, relapses and sequalae as well 
as their duration (“short and long term”) 2 and proportion.  Due to 
variation in clinical morbidity patterns several morbidity scenarios 
for each pathogen are required4. 
 
b Epidemiology: Epidemiology addresses incidence and mortality of a 
disease. Incidence can be characterized in more detail by overall 
and age specific incidence (= rate of cases per year) of clinical/ sub 
clinical/ latent and chronic infections4. Attention should also be 
paid to changes in disease incidence including their reasons4 and 
time trends, as well as geographical or seasonal variations3.  Epide-
miologic assessment depends on reliable data2 . In absence of reli-
able surveillance data estimates have to be used based on available 
literature or clinical medicine and epidemiology experts´ estima-
tion4. 
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b Risk groups/ Risk factors: Groups at greatest risk for infection (or 
one of the patterns of disease, e.g. more severe forms of disease) 
must be highlighted23,4. Age, sex, ethnicity, socioeconomic status, 
immunologic competence, geographical areas or other specific risk 
factors should be taken into account4. 
b Alternative measures: Besides the current treatment3 the availabil-
ity of other preventive measures that might be in favor of vaccina-
tion should be assessed2,3,5. Appropriate prevention interventions 
could be available for nosocomial infections (minimizing contami-
nation risks), waterborne infections (water supply), vector-borne 
microbial agents infections (vector control) or infections occurring 
in immunecompromized hosts (e.g. minimizing behavioral risks)4. 
The “new” vaccine should also be compared with other currently 
available vaccines6. All alternative measures should be compared 
with a vaccination strategy in terms of effectiveness, costs and prac-
ticality2,4. 
 
b Disease as public health problem5: The health impact of the disease 
in the population must be assessed3 to decide if the disease is of 
domestic health importance4. 
 b Social impact of disease: The social impact can, on the one hand, be 
seen as the influence of intensity of suffering (quality of life reduc-
tion) and frequency of survivors with sequalae or long term disabil-
ity on disturbing social structures (e.g. impact on families, caregiv-
ers) 2,3. The resulting stress on communities3, the public perception2 
(“fear of disease”3) and possible differences in real and presumed 
burden of disease2 should be taken into account. On the other hand, 
the magnitude of absenteeism from school or work of infected indi-
viduals themselves and their caretakers as well as associated costs 
can be seen as part of the social impact of disease2. 
b “Costs” of the disease: Health short- and long-term care utilization/ 
health system cost are the main part of the economic impact of the 
disease2-6. Additionally payments by patients and families and pro-
ductivity losses should be considered. To calculate the overall costs 
caused by a pathogen costs of each terms (hospitalizations, proce-
dures, medications, office visits, rehabilitation services, long-term 
institutional care) have to be multiplied with the proportion of pa-
tients receiving this care and finally summed up4. Due to the varia-
tion in health expenditures national data of “health care costs” for 
all services mentioned are therefore necessary4. 
Vaccine 
All authors include vaccine considerations in their decision making process. 
Issues to be considered are: 
b Vaccine characteristics3/ presentation6: The nature and characteris-
tics of the immunizing agent and the characteristics of the products 
(preparation, the stabilizing agents and preservatives, dosage, com-
bination, storage, handling, conservation and product format)3 must 
be known. Vaccine availability and registration, as well as the target 
indication/ population of the vaccine should be examined2.  
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b Vaccine supply: Data of vaccine manufacturers and their produc-
tion capacity must be collected3 . Potentially arising conflicts of in-
terest and differing quality criteria in case of national production 
facilities4 and the impact of vaccine introduction on any local vac-
cine producer5 should also be stated. 
b Administration schedule, number of doses, combination: The ad-
ministration schedule3 and possible alternatives to the optimal 
schedule2 should be assessed. The number of doses (number needed 
for complete immunization (initial series) and frequency of boost-
ers)4 and possible combinations must be taken into consideration. 
b Immune response: Issues to be assessed in this category are the na-
ture and characteristics of immune response3 and (type- specific) 
protection afforded, the critical determinants of immune response 
associated with protection2 as well as the expected duration of pro-
tection, the effects of waning immunity and consequences resulting 
in the necessity of possible repeated vaccinations (also regarding 
their expected coverage) 2. 
b Immunogenicity and failure: The immunogenicity in different 
population groups3 and the frequency of and risk groups for vaccine 
failure (despite optimal vaccination or when using alternative 
schedules)2 should be considered. 
b Efficacy and utilization: Efficacy can be seen as short and long-term 
reduction of disease and death by the vaccine3 or in other words as 
the capability to prevent a disease in immunized populations6. 
Availability of data has to be considered, especially if the study 
population is comparable with the target population and if the 
studies were performed in countries with similar disease epidemi-
ology6. Efficacy could also include assumptions on licensure ap-
proval and patient acceptance4. Utilization (coverage5) can be de-
fined as the proportion of the target population that will use the 
vaccine2,4. The data of population that has already been vaccinated 
should also be collected2.  
b Population effectiveness: Vaccine effectiveness reflects the per-
formance of the vaccine in the actual target population under pro-
grammatic implementation6 and therefore stand for “the net impact 
of the vaccine”5. Vaccine effectiveness is therefore usually lower 
than vaccine efficacy6. Effects can be seen as reduction of burden of 
disease3 and the reaching of a level of herd immunity by a sufficient 
vaccination rate2,3. 
b Safety:  Precautions3 and contraindications for vaccination and 
their proportion in the target population2 as well as the nature and 
frequency and consequences of short- and long term (severe3) ad-
verse events2 are major safety issues. Risk groups or risk factors for 
adverse events and differences in true and presumed burden of dis-
ease due to adverse events (perception of population) should also be 
considered2. For live attenuated vaccines the chance of reversion to 
virulence can be added2. Summing up, frequency, nature, severity, 
care required and public reaction should be assessed when safety is-
sues are included in calculations4. 
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b “Side-Effects”: Effects of antigen transmission of the targeted anti-
gen (e.g. on reduction in carriage3;  changes in antigenic composi-
tion, changes in virulence and transmissibility2 and therefore indi-
rect effects on reducing disease transmission5 ) and also of related 
antigens (e.g. replacement by other antigens3; emerge of new eco-
logical niches2) should be considered as possible long-term effects. 
Shifts in age-distribution of the disease might occur and the re-
duced pathogen transmission under vaccine pressure might lead to 
enhanced vulnerability of specific sub-populations2. Possible inter-
actions/ interference with other vaccines2,3 should also be consid-
ered as well as the impact of the new vaccine on resistance to anti-
biotics/ antivirals3 . 
Immunization strategy 
Goals of the new vaccine implementation should be expressed precisely in 
the decision making process.  
b Existing recommendations/ guidelines: To assess the immunization 
strategy, availability of existing recommendations or guidelines to 
be searched for and taken into account3.  
b Goal of prevention/ specific program objectives: Different goals 
(disease control, elimination or eradication) as well as specific pro-
gram objectives (e.g. reduction of incidence or complications) 
should be defined3.  
b Alternative strategies/ specific operational objectives: Selective vac-
cination versus universal or catch-up vaccination and specific op-
erational objectives (e.g. coverage for different target groups) 
should be weighted3.  
b Different program delivery strategies and systems:  Public versus 
private vaccine delivery or vaccination in schools versus in primary 
care settings should be discussed for example3. 
Conformity of programs 
The planned program should be compared with other existing or planned 
programs in other countries3. 
Cost effectiveness 
The cost effectiveness category is the most difficult to compare because all 
authors chose different approaches. It can be seen as one step beyond oth-
ers3,5,6, an intermediate result (after assessing other main factors) 2 or a cen-
tral approach respective to the outcome4 of the analysis. 
b Vaccine costs: Costs to be considered are:  
- Costs of research and development4: Assessing vaccines al-
ready available on the market for implementation in na-
tional immunization programs, will allow neglecting the 
pre-licensure expenditures. 
long-term  
unintended effects 
clear defintion of goals 
of implementation & 
strategies to  achieve 
these goals 
comparison of 
conformity with  
other national health 
programs 
different approaches: 
central criterion or one 
among others 
cost categories:  
 
R & D costs 
Rational Vaccination Policies - decision support 
 
22 LBI-HTA | 2008 
- Costs of the vaccine: The cost per dose of the vaccine has 
to be given. It should be noted that these costs depend on 
the number of companies distributing the vaccine and 
their marketing strategies3. 
- Costs of the vaccination program: In addition to the vac-
cine cost itself, the cost to administer the vaccine has to be 
added and then multiplied with the number of doses 
needed and the size of the target population4. This will re-
flect the annual vaccine use costs, if the “steady state” is 
already reached. Costs during initial use might differ 
(once-only versus yearly costs2): decreased costs might oc-
cur because the usage depends on how familiar a health 
care system and the target population are with the new 
vaccine. Increased costs also might result from "catch-up" 
usage of the new vaccine beyond the target population4. 
Additionally costs from a “societal perspective” including 
direct and indirect costs for families and the health system 
should be considered3. Further costs for implementation 
and running of the program3 and for monitoring safety and 
effectiveness of the vaccine and the program2 should be 
taken into account. 
b Effectiveness of the program: Evidence of short and long-term ef-
fectiveness of the program (incl. the reduction in disease incidence, 
complications, sequalae and mortality) has to be analyzed3  
b Economic,  social and other (“non-health”) benefits are:  
- savings on health care costs 2-6 
- improvement of life expectancy and quality of life for indi-
viduals (“QALYs gained”) 2-6 
- possible (positive) impacts on caregivers and communities, 
productivity gains and other indirect benefits (like re-
duced microbiological resistance or reduced emergency 
room overcrowding)3. 
b Economic evaluation of alternative measures: the cost effectiveness 
ratio of vaccination has to be compared with alternative preventive 
measures (how many infections could be prevented by other vac-
cines/ health care interventions and what would be the savings on 
costs of health care?) 2-6. For this comparison costs and health ef-
fects using current forms of prevention and treatment or vaccines 
have to be known4.  
b Testing underlying/ alternative assumptions:  
- Sensitivity analyses testing alternative assumptions (dif-
ferent morbidity/ clinical scenarios, quality adjustment 
weights, costs of care, vaccine development, utilization,...) 
have to be carried out to show the robustness of the eco-
nomic model3,4.  
- Using different schedules or different strategies (e.g. high 
risk immunization) will influence cost-effectiveness analy-
ses and therefore must not be neglected2.  
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- The maximum impact of a new vaccine is the ideal vaccine 
benefit calculated under the assumption, that the vaccine 
is fully efficacious and utilized (optimal conditions)4.  It 
should be compared with the cost-effectiveness for incom-
plete use and efficacy4. In case of vaccines under develop-
ment the impact of developing time and resources has ad-
ditionally being taken into account4. 
- The results of all analyzes should be compared with simi-
lar studies and their pertinence for local settings should be 
considered3. 
b Time interval: Time intervals between the age of vaccine use and 
the age at which health effects and related costs are experienced 
have to be regarded2,3. Reasons for and possible ethical conse-
quences of discounting for costs and health benefits should be dis-
cussed4.  
Acceptability 
The acceptability of the new vaccine or a whole new program can be evalu-
ated by assessing the 
b Public’s perception of disease risk and severity as well as the de-
mand for the immunization program at target group and popula-
tion at large level3, concerns about rapidly enough changing NIPs 
(modernization) in public’s opinion2  
b Demand and acceptability by health professionals and political au-
thorities3 
b Time effects: Adding a new vaccine to a NIP could increase or de-
crease the overall perception of the value of immunization5. During 
a vaccination program the balance between presumed adverse 
events and beneficial effects may shift in time2.  
Feasibility 
Feasibility addresses practical consequences of the planned vaccine imple-
mentation and reflects the opportunity of implementing the new program3. 
Differences in the approach can be observed. Some authors completely ne-
glect issues of implementation during the decision making process4 or first 
consider them after the fact5,6. 
Issues to be considered are the 
b Assessment of the overall NIP performance5,6 and the effectiveness 
of the primary care system2 ahead of introduction of any new vac-
cine 
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b Availability of long term supply3 (see vaccine) 
b Availability of funding for vaccine purchase5,6  
b Chance of integrating the new vaccine in existing immunization 
programs and schedules3: Often average schedules for combined 
administration have to be chosen for practical and economic rea-
sons (NIP is likely and perhaps necessarily a compromise)2. Reduc-
ing the number of vaccines delivered to children by combination 
vaccines can increase the level of acceptance and utilization4, while 
the complexity of the vaccination schedule or multiple injections 
administered at a single visit might lower compliance2. 
b Impact of the new program on existing services3 is influenced by fi-
nancial concerns about sustainability, concerns about potential in-
crease or complication of the workload for the staff and the risk of 
reducing the credibility of the NIP5. 
b Accessibility: Whether or not the new vaccine is accessible for the 
target population has to be considered3 (access, waiting times, re-
minders)2 and if the desired levels of coverage will therefore be 
reached3.  Special attention should be paid to difficult-to-reach 
groups2. Furthermore, other concerns regarding poor compliance 
that hindered successful vaccine implementation in the past should 
be considered (e.g.: lack of parental awareness, competing parental 
priorities, parental complacency, inappropriate interpretation of 
contraindications, concerns regarding adverse reactions)2  
b Existence of operational planning and implementation commit-
tees3, the availability of human, technical and financial resources 
for distribution, conservation and administration of the program3, 
the availability of documentation/ consent forms3, the availability of 
recording/ registering systems for vaccine administration3, because 
poor records keeping also minimizes compliance2, and the availabil-
ity of resources for marketing/ communication to the public and in-
formation and training of health professionals3 
Surveillance 
The desirability and necessity of monitoring and evaluation of the altered 
program should be beyond all questions. Therefore most authors include 
main issues of surveillance in their decision aids2,3,5, sometimes even provid-
ing a separate post-introduction evaluation checklist for the assessment of 
overall implementation6. 
b Coverage: Vaccine coverage and utilization should measure general 
acceptance and identify regions or groups with lower coverage2. 
These could/ should be added by surveillance of quality of services3  
and trust in the NIP2. 
b Epidemiology2-6: The reduction of burden of disease2 can be deter-
mined by surveillance of reduction in disease incidence, complica-
tions, sequalae and mortality3. Simultaneously time trends can be 
detected and observed2. 
b Safety: The frequency and nature of adverse events has to be ob-
served2-6. 
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b Immune surveillance and surveillance of microbial population dy-
namics2: markers of protection should be observed in the general 
population, subgroups with waning immunity and also altered cir-
culation pathways should be identified. The microbial population 
dynamics must be monitored2. 
b “Linking systems” 3: information systems in general6 and systems 
for  linking health outcomes databases (immunization registries 
and population registries) must be available3 
Research questions/ Uncertainties 
Vaccines should be primarily excluded from analysis, if only insufficient ba-
sic scientific information is available4.  
Issues to be considered are  
b uncertainties about the nature of the infective antigen, major con-
tributors to a disease or other pathogenetic factors4 
b main uncertainties concerning the effects of the vaccine and the 
impacts of program3, need for a pilot immunization program3 
b ongoing/ planned research projects (e.g.: vaccine development, im-
munigenicity, efficacy, safety) 3  
b need for research to assist evaluation, planning or decision-making3 
Because the information gathered during the decision making process is not 
stable, evaluation and updating of the program will be necessary after im-
plementation2. 
Equity 
b Universality, accessibility and gratuity of services for the most vul-
nerable population groups3 are political responsibilities4 that can-
not be addressed by cost-effectiveness approaches (e.g. allocation of 
resources- need for specific populations). Equal opportunities for 
vaccination and equal access to information are therefore chal-
lenges for governments2. 
b Introduction of expensive new vaccines2: The high costs of (new) 
vaccines that may prohibit universal vaccination even when the 
burden of disease is high will place wealthy and well-informed in-
dividuals at an advantage2. Therefore small NIPs plus voluntary 
packages that are offered in some countries inevitably lead to ine-
qualities in comparison with comprehensive NIPs for the whole 
target population2.  
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Ethical considerations 
All decisions to implement or withhold a vaccine always must be taken as se-
riously and discussed from a scientific as well as from an ethical point of 
view2. Some ethical and value judgments can be built into analytical models, 
others have to be discussed separately4. 
Ethical considerations include: 
b Appropriate informed consent forms and the protection of confi-
dentiality3: Particularly for vaccinations that are not mandatory, in-
formation is necessary to ensure that the population is capable of 
making informed choices3. 
b QALY versus DALY: the question if an additional year of life 
should have the same value regardless of the receiver’s age remains 
an ethical question2. Under QALYs, an additional year of life of the 
recipient has the same value regardless of the recipient’s age. In 
comparison, the use of DALYs would assign greater value to years 
of life gained during the economically productive young adult 
years, assuming a greater social value because old and young de-
pend on them. Choosing QALYs might therefore be judged more 
appropriate if the value of extending the individual’s life seems 
more important than the value of the individuals’ lives to others4.  
b Adjusting for differences in average health status of population at 
different ages, nevertheless may weigh years of life at different ages 
by quality4. 
b Value of life extension with and without disabilities2,4: Vaccines 
used to prevent (opportunistic) infections in people with predispos-
ing conditions or preexistent disabilities that initially caused a re-
duction of the quality of life (chronically ill or elderly people) will 
not achieve the same gain in health related quality of life as preven-
tive vaccines given to healthy people4. Prioritizing vaccines prevent-
ing morbidities (not mortality) according to that method of valuing 
health benefits potentially discriminates persons with disabilities 
(if disability reduces benefits from treatment/prevention or makes 
the treatment/prevention more costly) 4. The value of life extension 
on different levels of health related quality of life therefore remains 
a controversial ethical issue2,4. 
b Applying discount rates to costs and health benefits gives a period 
of well-being greater value the sooner it occurs4, an early in life 
health gain is therefore assigned a greater value2. This might be 
ethically controversial, too4.  
b Including non-health benefits of vaccination: from a public health 
perspective non-health benefits that are not included in a cost-
effectiveness approach pose ethical questions, but  also an inclusion 
might lead to problems2,4: For example taking lost wages due to ab-
sence from work into account, would reduce the value of prevention 
against diseases acquired during nonworking years of life or occur-
ring more frequently in lower-income populations4.  
b Comparing total health benefits of vaccines: From a public health 
perspective in allocating resources, this approach of looking at 
overall benefits is coherent4. Reducing the total burden of disease 
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does not differentiate in disease distribution4. Considerations of 
fairness arise if a decision is only based on maximizing cost-
effectiveness2. Priority judgment of aggregating small benefits for 
many can lead to ethical questions because in many peoples’ minds 
avoiding a disease with an extremely large burden of disease has a 
higher priority even if the disease is less widespread4. The contro-
versy remains if the maximum aggregate benefits should be 
achieved by large benefits for a few or small benefits for many4.   
b Vaccines avoiding diseases (or treating them) in primarily sick peo-
ple4: There is no objective basis for determining how much health 
gain in overall well-being should be achieved, therefore the priority 
of treating the sickest remains an unsolved problem and a political 
responsibility4. 
b Setting priorities in vaccine development4: Funding only one of two 
vaccines against diseases that result in almost the same burden of 
disease may seem unfair to those who end up with that disease 
which did not receive vaccination funding. 4 This argument is 
somewhat mitigated because vaccines are developed mainly against 
diseases that are not life-threatening and nobody is able to predict, 
which disease one will develop over the years4. 
Legal considerations 
b Use of a vaccine in a different schedule as originally recommended 
by the manufacturer3: Even if there might be some evidence that a 
single-dose vaccine could be as effective as the original schedule, 
the lack of clinical trials’ data would lead to legal actions in case of 
vaccine failure3. 
b Legal issues as barrier in vaccine development and licensure4: Vac-
cine producers require legal protection from lawsuits (e.g. devel-
opment of vaccines that could be administered to pregnant women 
in the future) that address liability concerns. A vaccine injury com-
pensation program already successfully has encouraged the devel-
opment of vaccines for children4.  
b The implementation of compensation for people who suffered seri-
ous adverse events from vaccinations already exists in some coun-
tries like the U.S. 2. 
Political considerations 
It should be stated if 
b the decision will be free of controversy3 and if  
b it will produce immediate political benefits or risks3. 
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4 Discussion - Feasibility of analytical frameworks: 
a stepwise approach 
Gathering information on the issues to be addressed in a decision process 
concerning the implementation of a new vaccine as provided in the frame-
work comparison above, results in a most comprehensive as well as detailed 
list of categories. However the pertinent question of whether this approach is 
feasible for decision makers at all arises. Some of the categories will be be-
yond all questioning. Others, however, should be discussed in terms of rele-
vance and chronology. 
A rational approach that could be the basis of a discussion among decision 
makers would be a stepwise procedure. A draft proposal is given in Figure 
4-1) 
Figure 4-1: Analytical steps in the decision making process 
4.1 Step 1:  Public Health relevance, alternative  
measures, immunization strategy  
and conformity of programs 
Some fundamental considerations concerning the disease as a public health 
problem, aims of the planned immunization strategy, the comparison with 
other programs and the availability of sufficient basic research data could be 
a starting point for the decision process and should be taken into account 
prior to further analyses. 
The question of whether or not the disease is a public health problem for the 
country in which the adaptation of the immunization program is planned, 
should be considered before further analyses, though the precise answer, if 
for policy process:  
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the burden of disease justifies a control program can’t be given until all is-
sues of disease burden and possible other alternative measures are weighted 
in step 2.   
In a global world, international organizations play a key role in providing 
general recommendations on immunization strategies. In response to global 
immunization challenges, including the need to protect more people and in-
troduce new vaccines, the World Health Organization and the United Na-
tions Children's Fund, in consultation with other partners, have developed 
the Global Immunization Vision and Strategy/GIVS for the period 2006-
20157. GIVS is a framework that offers policy-makers and stakeholders a 
unified vision of immunization and a set of strategies from which countries 
can select those most suited to their specific needs.  
Immunization represents a priority issue in the agenda of EU member states 
as well. Moreover many EU wide projects concerning vaccination – funded 
by European Commission - are in place at the present. The European Centre 
for prevention and disease control (ECDC)8 states that providing evidence 
based scientific advice on vaccine policies and  strengthening surveillance of 
vaccine preventable diseases (VPD) in the EU in order to provide more in-
formation for scientifically sound decisions on vaccinations are VPD priority 
areas. 
The goal of prevention (disease control, elimination or eradication) as well 
as specific program objectives (e.g. reduction of incidence or complications) 
might already be defined in international documents. Alternative immuniza-
tion strategies (selective vaccination versus universal or catch-up vaccina-
tion) and specific operational objectives (e.g. coverage for different target 
groups) should be primarily discussed and finally weighted after the follow-
ing steps.  
Especially if there are no universal recommendations available, a planned 
program should be compared with other existing or planned programs in 
other regions/ countries. Looking across borders should facilitate considera-
tions in the first planning phase. Providing updated online information 
about national vaccine schedules is one of the outcomes of the Surveillance 
Community Network for Vaccine Preventable Infectious Diseases (EU-
VAC.NET)9 project. Facilitating the flow of information between European 
countries is also an objective of the Vaccine European New Integrated Col-
laboration Effort (VENICE)10 project. 
Another aspect that might be considered previous to further analysis refers 
to scientific uncertainties concerning the vaccine. It would be a negligent act 
to introduce a new vaccine despite insufficient basic data. The answer to the 
question concerning what data should be available to be considered as suffi-
cient cannot be given in this paper but should be discussed seriously. Due to 
restricted observation times during clinical trials, uncertainties on the long 
term effects of a vaccine will always remain. Duration of vaccine protection 
is one of these crucial issues directly affecting the cost-effectiveness analysis. 
Current literature does not shed light on the degree to which uncertainties 
had been accepted in the past. Also unavailable, is literature on how great 
the estimated benefits had to be in order for the vaccines to be introduced 
despite the missing information. 
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Promising ongoing or planned research projects in the same field of target 
disease could not only strengthen a decision to withhold a vaccine but also 
justify a postponement of analysis as does the lack of capable assistance for 
evaluation, planning or decision-making 
4.2 Step 2: Disease and Vaccine 
The two main criteria - disease and vaccine - that all authors considered as 
key parameters in the vaccine decision making process2-6 should be assessed 
in the next step.  
The assessment of epidemiology, risk groups and clinical manifestations de-
pend on reliable surveillance data. Insufficient surveillance systems, espe-
cially in diseases that are not reportable events and the lack of adequate data 
linkage (e.g. between physicians, health insurances and health authorities) 
due to considerations of privacy protection hinder conclusive argumenta-
tion.  Therefore often less precise estimates have to be used based on avail-
able literature or clinical medicine and epidemiology experts´ estimations4. 
To increase data quality of epidemiological surveillance and control of vac-
cine-preventable diseases in the European Community, the EUVAC.NET9 
project was created. Currently only surveillance data and annual reports 
about measles, mumps, pertussis and varicella and diseases fact sheets and 
case definitions of these diseases plus rubella are available on the EU-
VAC.NET web site9.  
A discussion on which criteria should be fulfilled by the burden of disease 
measure is necessary. A measurement applicable for various conditions 
should be used4. Though QALYs may have possible disadvantages as dis-
cussed, QALYs can serve as basis for disease burden measurement. In terms 
of quality adjustments, various instruments are availablei. To compare the 
burden of disease with a population not affected by the disease, basic data of 
these quality adjustments for average population health states (at different 
ages) are necessary4. Though published literature currently uses QALYs 
rather than DALYs weighing procedures in particular often remain unclear.  
Costs caused by the disease or its consequences vary in different healthcare 
systems4. The influence of the perspective from which the cost-analyses are 
conducted will be discussed later in conjunction with the cost-effectiveness 
matter. 
The social impact of disease is probably the most difficult parameter to as-
sess. While data of the extent of quality of life reduction and the frequency 
of survivors with sequalae or long term disability might be available, their 
impact on caregivers or even the community is hypothetical in the majority 
of cases4. Therefore one author4 excluded matters of time or costs saved by 
patients or their caregivers from analyses. But if sustainable time cost esti-
                                                             
i Stratton4 chose the Health Utility Index (HUI) for weighting. HUI Mark II charac-
terizes morbidity by using seven health attributes (sensation, mobility, emotion, 
cognition self-care, pain and fertility). Alternative instruments as the Disability-
Distress Index (DDI), Quality of well-being scale (QWB), World Bank/ WHO dis-
ability (used for calculating DALYs) would be available. 
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mates are available for a disease they could and should be incorporated in 
the analyzing model4. 
Published literature provides no limits (cut-off points concerning epidemi-
ological indicators or burden of disease measures) on when a disease and its 
consequences should be considered a severe public health problem. In some 
cases general recommendations are available on the strategy (e.g. schedule 
and coverage) that should be followed depending on the prevalence of the 
disease. These disease specific immunization policy recommendations are 
available on the WHO Immunization, Vaccines and Biologicals website11.  
Current and alternative measures should be outlined in detail at the end of 
burden of disease assessments. Their effectiveness and costs must be calcu-
lated to allow comparison with the planned measure and answer whether or 
not the planned immunization is the best strategy to control the disease.  
Basic analyses can be conducted on the assumption of 100% vaccine supply 
availability meeting the demand4. Nevertheless, one should keep in mind 
that inadequate supply has hindered extensive use of some vaccines in the 
past4. 
In order to determine requirements for vaccine handling and storage or to 
draw conclusions on possible combinations and the immunization schedule, 
the vaccine characteristics must be known. If combinations are available, 
this might influence not only costs or effectiveness but also vaccine utiliza-
tion (likely to increase)4. The number of doses needed for complete immuni-
zation (initial series) is suggested and approved by clinical trials. In new 
vaccines the frequency of boosters is mainly based on estimates and com-
parison with other vaccines due to the short trial observation period. All data 
or further estimates on immune response, including those on vaccine failure 
must be outlined to design different scenarios (influencing costs of the pro-
gram, coverage and population effectiveness).   
Assumptions of 100 % effectiveness and utilization could be used to asses 
the ideal vaccine benefit (ideal population effectiveness)4. Setting efficacy 
levels at (realistic) less than 100% will influence the results of analyses by 
reducing health benefits and therefore also derogating expected savings in 
health care costs4. On the other hand assumptions of utilization rates lower 
than 100% reduce health benefits and expected savings in health care costs 
but also simultaneously lower costs of vaccinating4. Coverage levels to be 
reached might be given in WHO recommendations already mentioned above 
(e.g. for varicella immunization12). Ideal (100%), desired and less optimistic 
scenarios must be compared to point out discrepancies in the (expected) 
benefits, taking care of effects on herd immunity or side effects4.  
Because clinical trials have to prove the safety of new vaccines and possible 
contraindications previous to approval of the vaccine all vaccines are as-
sumed to be safe at the time of vaccine implementation. For this reason, 
safety issues might play a minor role in initial vaccine assessment (presumed 
infrequent and usually not severe) and be excluded from basic analyses4. As 
part of the post-introduction surveillance, safety surveillance gains impor-
tance in detecting long-term negative consequences or rare adverse events 
over a longer time period (because pre-approval trials may not capture rare 
adverse events)5,6. If adverse events occur they will lead to a reduction in 
health benefits, increase the costs of care and might limit public acceptance4.  
Also relevant is that risk-benefit ratios may vary between countries: risk of 
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adverse events might be outweighed if the morbidity and mortality of a dis-
ease is domestically high5,6. 
Most side-effects will be unknown at the time of vaccine introduction, 
but some conclusions might be drawn from observations in countries 
where the vaccine already is in use or from effects that were observed af-
ter vaccine introduction of other vaccines (see surveillance). Addition-
ally, computer simulations might be used to detect the impact of differ-
ent strategies13.  
4.3 Step 3:  Cost-effectiveness 
The cost-effectiveness analysis could be the third step in the decision proc-
ess. Simplified answering of the question concerning whether or not the vac-
cine is a good investment can be given by weighing the net costs of the pro-
gram (total cost of additional resources minus savings in treatment and 
other costs) against the net health impact (disease, disability and death 
avoided minus adverse events from the vaccine)5 . In other terms a cost-
effectiveness ratio is expressed as cost per unit of health benefit gained4. For 
the sake of completeness one should note that there are differences between 
cost-effectivenessii, cost-benefitiii and cost utilityiv analyses that are not out-
lined here in detail. 
No controversy exists about main costs and benefits that should be incorpo-
rated in the analysis (vaccine costs/ program costs, effectiveness of the pro-
gram, economic benefits). No controversy exists either on the fact that time 
effects have to be considered and underlying assumptions must be tested 
(sensitivity analyses). The necessity of comparison with alternative measures 
should be beyond all questions as well. 
But disagreement exists on which costs and benefits should be included. The 
results of cost-effectiveness analyses depend on the perspective from which 
they are carried out. From a societal perspective all health outcomes and 
costs regardless of who experiences them must be taken into account4. 
Therefore the results of selective analyses carried out by government agen-
cies, third party payers or vaccine manufacturers usually differ from those 
societal perspective analyses4.   
Costs from a societal perspective would include direct and indirect costs for 
families, the community as well as those for the health system, for example 
co-payments, costs for transportation or productivity losses and lost wages. 
The main obstacle in the discussion about indirect costs could be the lack of 
appropriate data. The duration of care for an ill child might be possible to 
estimate, but the necessity for care of ill adults can not be captured un-
                                                             
ii Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the 
relative expenditure (costs) and outcomes (effects) of two or more courses of action 
iii Cost-benefit analysis (CBA) is a formal discipline used to weight the total expected 
costs against the total expected benefits of one or more actions in order to choose the 
best or most profitable option. 
iv Cost-utility analysis (CUA) is a form of economic analysis used to guide 
procurement decisions  (e.g. health technology assessment (HTA)). 
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equivocally4. Just to outline the diversity of included indirect costs, examples 
from background material papers are given in Table 4-1. 
Table 4-1: Examples for indirect costs considered in cost-effectiveness analyses 
indirect costs vaccine 
lost productivity (calculated based on the 
average production value of one hour of 
work per parent) due to care-giving14 
Meningococcal vaccine 
medical visits, loss of earnings due to 
illness or mortality15 
Hepatitis B vaccine 
work time lost, lost productivity resulting 
from premature death or severe disability 
(parents´s time for caregiving or because 
of their own disease)16 
Varicella vaccine 
not included (due to “diversity”)17 Pneumococcal vaccine 
not included ?18  Human Pappiloma Vaccine 
no consideration of productivity losses 
though statement of considering social 
health care costs19 
Hepatitis B vaccine 
 
Benefits achieved by vaccination for the vaccination recipient, e.g. improve-
ment in life expectancy and in quality of life are included in all analyses2-6. 
Non-health benefits or benefits for others are not generally included in 
analyses, consequences of excluding those “real benefits” were already dis-
cussed from an ethical point of view.  
Implications of discount rates depend on the duration of the time interval 
between vaccination and expected effects. Stated discounting rates for costs 
vary between zero and five percent in literature. If all authors also dis-
counted benefits for the same amount (as Stratton4 did), cannot be answered 
in a brief overview and would have to be analyzed separately. 
The given variation of key issues that might be included in an analysis and 
the examples for various viewpoints and approaches highlight that various 
factors influence cost-effectiveness analyses. Therefore comparisons of dif-
ferent cost-effectiveness analyses have to be conducted with caution. Beyond 
the variation in included criteria, the bases of the underlying assumptions 
should be noted (e.g. surveillance systems, published literature, expert’s 
opinion).   
Key factors that essentially influence costs per QALY gained could be 
summed up as4:  
b the number of vaccination recipients vs. number of cases,  
b the time between vaccination and prevented disease,  
b and the differences in age groups, mortality or lengths of periods 
spent in a disabled state.  
Keeping these factors in mind also assists in the rational comparison of dif-
ferent outcomes of analyses. 
If costs per QALY gained by the planned vaccination program are finally as-
sessed, rational decision making then would be facilitated, if this outcome 
could be classified in some way. Available literature provides few informa-
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tive bases for this. Stratton4 gives such a ranking for the USA, placing vac-
cines within general levels. (see Table 4-2) 
Table 4-2: Favorability of vaccines ranked by costs per QALY (US) 
level favorability costs 
level 1 most favorable saves money per QALY gained 
level 2 more favorable costs <10000$ per QALY gained 
level 3 favorable costs >10000$  and < 100000$ per 
QALY gained 
level 4 less favorable costs >100000$ per QALY gained 
 
Kimman2 states when vaccines are considered to be cost-effective in the 
Netherlands (see Table 4-3).  
Table 4-3: Cost-effectiveness ranked by costs per QALY (Netherlands) 
cost-effectiveness costs 
cost-effective costs <20000€ per QALY gained 
intermediate cost-
effective 
costs >20000€  and < 50000€ per QALY gained 
not cost-effective costs >50000€ per QALY gained 
 
Cost-effectiveness analyses and groupings can aid rational approaches 
whether to implement a new vaccine or not. Making rankings used in differ-
ent countries public would enable serious discussions. Nevertheless rankings 
cannot determine whether the health benefit is - in the end - worth the cost. 
Weighing remains a value judgment4. 
Corresponding to the commonly used “number needed to treat” (NNT) a 
measure “number needed to vaccinate” (NNV) has been introduced. The 
number of people (or the number of vaccine doses) to prevent one event (e.g. 
hospitalization or death) per year and consequently the associated vaccina-
tion costs could be defined by this measure. This procedural method could 
provide additional comparable and reproducible results across different vac-
cination strategies. A PubMed search for “number needed to vaccinate” cur-
rentlyv only reveals 21 hits, reflecting that this approach is not well-
established. In some cases the NNT20 is given. This heterogeneity further 
impedes rational vaccine comparison. 
 
                                                             
v Search term: „number needed to vaccinate“, full text search carried out on 
18.1.2008 on http://www.ncbi.nlm.nih.gov/sites/entrez  
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4.4 Step 4: Acceptability, Feasibility, Equity  
and Ethical Considerations, Legal and  
Political Considerations 
Acceptability of the new vaccine and the program by patients and health 
professionals is a key factor for the success of the program. In the past, the 
demand for a new program has often been a powerful argument for decision 
makers at the political level3.  For example a meningococcal program in 
Canada was introduced though varicella vaccination was the most favorable 
from an economic point of view and a pneumococcal program would have 
been able to achieve the greatest disease reduction at the time of considera-
tion3.  Likewise the introduction of a meningitis C vaccine in the Nether-
lands was (partly) based on the judgment, that it would reduce public anxi-
ety2 . 
The public’s perception of disease risk and severity causing the demand for 
an immunization program can be manipulated to a high degree and has to 
be handled with care. All lobbies that would profit from the introduction of 
a vaccine could outweigh other rational considerations. A health market 
should differ from supply and demand models of other markets, mainly be-
cause the “product health” cannot be purchased. Different indirect cash 
flows, stakeholders and issues of fairness and ethical considerations have to 
be taken into account. Therefore a rational decision remains questionable if 
just demand forces vaccine introduction.  
Nevertheless acceptability is necessary for the successful implementation of 
a new vaccine and participation as a basic principle of health promotion will 
enhance positive health outcomes.  
Operational issues should be considered during the decision process: Avail-
ability of funding is an important concern, especially if the new vaccine is 
implemented in a public financed program. Otherwise if the new vaccine is 
added as a voluntary extension of the regular NIP and has to be (at least 
partly) paid out-of-pocket by patients themselves, accessibility of target 
groups will be influenced and consequences on broadening the social gap 
have to be considered. 
Most feasibility concerns address successful implementation. Different 
delivery systems, schedules and impacts on existing services (health-care 
“side effects”) will influence costs and success of the program. If the tar-
get group of a new vaccine differs from those of commonly used vac-
cines, new strategies have to be developed for successful implementation 
(e.g. for adolescents)4. 
The lack of instruments to enhance feasibility (e.g. documentation forms or 
resources for communication or registering systems) has to be discussed and 
resolved (necessity of establishing missing instruments and allocating addi-
tional human, technical and financial resources).  
Value judgments concerning equity and ethical considerations have to be 
clarified. Most of these judgments cannot be built in cost-effectiveness mod-
els4. Therefore it is necessary to keep in mind that rational approaches to 
implement or to withhold a vaccine are on the one hand limited but on the 
other hand endorsed by further ethical and equity considerations.  
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If a vaccine will be administered in a schedule that differs from the one rec-
ommended by the manufacturer because of the need to match the existing 
NIP due to enhanced feasibility, legal considerations have to be taken into 
account3. Though decision-makers bear responsibility for their decisions, li-
ability concerns mainly affect vaccine manufacturers4. 
A rational approach would be supported by including a disclosure step in 
the decision process. This would bring to light any potential controversies or 
immediate political gains that could influence or appear to influence the de-
cisions being made. 
Including the ability to evaluate in the decision making process, highlights 
the need for reviewing the performance and success of a target-orientated 
program. Issues that surveillance systems should cover will be discussed 
later with regard to the revision chapter. 
At the end of step 4 it could be necessary to introduce a new stand-alone 
criterion „side effects“ that should sum up “side-effects” according to 
each other criterion. Otherwise the chance of missing additional side-
effects of vaccine introduction increases.  
b “vaccine side effects”: microbial population dynamics, replace-
ment diseases, age-shifts  
b “feasibility side effects”: impact on health care system, work-
load, credibility of the NIP 
b “utilization side effects”: impact on the utilization of other pre-
ventive measures or for example on diagnostic tests themselves 
(e.g. introduction of HPV vaccine could result in the loss of pre-
cision in Pap test screening - false positive rate and even false 
negative rate increase - when the prevalence of HPV infections 
falls and the volume of and the time for performances stay the 
same).  
4.5 Step 5: Decision Making  
The ongoing research project VENICE (Vaccine European New Integrated 
Collaboration Effort)10, funded by the European public health action pro-
gram, Work package 4 (Priority setting and decision making) aims at en-
couraging a rational approach to vaccination policy and the decision making 
processes in Europe. This objective is addressed by promoting the exchange 
of experience and expertise through 
b “sharing of information about recent and current studies per-
formed, the methodologies used and the outcomes of the expertise 
for vaccination policy decisions; 
b increasing the efficiency of work by reducing redundant analysis 
and sharing the tasks when the various member states are faced 
with similar issues such as integration of a new vaccine in the im-
munization schedule; 
b increasing the level of expertise to a common high standard within 
the enlarged EU, including on public perception of vaccinations 
and techniques and methods to gage such perceptions, e.g. by suit-
able questions in surveys; 
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b setting the basis for European immunization schedules through en-
suring common scientific background for future vaccination deci-
sions.” 
 
The project started almost at the same time that the approvals of HPV and 
Rotavirus vaccines were granted. Therefore the decision making processes of 
these two vaccines are used as real-time vehicles to explore how rather than 
why the vaccines are implemented in or withheld from the national immu-
nization program. The questionnaires sent to the participating countries are 
currently analyzed. Only first results have been published, reporting the 
current situation about recommendations for Rotavirus and Human Papil-
loma Virus vaccines in each country1. A more detailed manuscript on the de-
cision making processes will be available in spring 2008. 
After consideration of pre-analysis issues (step 1) the result of the cost-
effectiveness analysis (step 3) that was mainly based on data on disease and 
vaccine (step 2) can be added and probably weighted by concerns reported in 
step 4. A systematic analysis of all outlined fields is necessary as input for 
the final decision to avoid major influences of other factors (like political 
pressure or public anxiety). 
All authors agree that final decisions are a political responsibility2-6. But de-
cisions on implementing new vaccines in national immunization programs 
are public health decisions. Therefore interdisciplinary teams should evalu-
ate and discuss the previous steps in order to achieve a most comprehensive 
analysis and to avoid influences of single stakeholders. Organizational struc-
tures supporting the decision making, e.g. scientific boards or advisory 
committees and decision making routes vary in different countries. These 
differences as well as the unequal power to implement decisions on national, 
federal state or community levels likely influence not only the success of a 
program but also the decision itself. Neither these effects nor the possible 
weight of different health care systems (mainly Bismarck type health insur-
ance system vs. tax based systems vs. private systems) have been considered 
as part of this study.  
Decision makers should notice that even the best rational approach and 
most comprehensive evaluation is limited by remaining uncertainties con-
cerning long term consequences, future vaccine prices and economic circum-
stances for example2. This fact does not impair a rational decision making 
process and must not be used as an excuse not to utilize.  
At the end of this chapter on decision making it is necessary to say that 
comprehensible arguments for all possible decisions have to be made public. 
It might be easier to convince patients and health professionals of the need 
for a new vaccine rather than to argue on behalf of withholding it, especially 
if the perceived demand is high. But it might be even harder to explain a 
withdrawal of a previously introduced vaccine unless there are severe nega-
tive and unexpected consequences2. In any case, a rational decision making 
approach will facilitate the public’s confidence in the decision and its reali-
zation. 
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4.6 Step 6: Implementation 
Some of the concerns of successful vaccine introduction that must be consid-
ered during the decision making process have already been discussed mainly 
in the feasibility chapter. The implementation itself is not part of this proc-
ess anymore. Therefore it will not be outlined in any more detail in this 
study. 
4.7 Step 7: Surveillance and Revision  
The importance of discussing post-introduction surveillance in a study 
about decision making can be justified by the necessity of reviewing conse-
quences of the primary decision. Also pertinent is that the process of pre-
introduction decision making is not completed by the decision itself. Post-
introduction surveillance does not only serve as a tool for performance 
measurement, it also might reveal unforeseen factors that force decision-
makers to alter their new vaccination program. 
Coverage rates of the new vaccine in the whole population or specific groups 
might be lower than expected and endanger, for example, the goal of reach-
ing herd immunity. This might lead to age-shifts of the disease (see also 
“other side effects” below) or influence disease severity as previously dis-
cussed.  
Besides these direct effects, the impact of the introduction of a new vaccine 
on the coverage rates of other vaccines must be observed. Concerns of per-
ceived overloading of the NIP resulting in lower vaccine utilization in gen-
eral must be taken seriously. Also to be looked at is whether the immuniza-
tion program is still working well enough to justify the introduction of the 
new vaccine, aiming at the allocation of limited resources for the best possi-
ble preventive measures to protect a population.  
Immunosurveillance can identify risk groups with low coverage rates due to 
incompliance21. Recent measel outbreaks in Germany22, Switzerland23 and 
other European countries reflected suboptimal coverage levels. In this case 
appropriate measures to increase coverage rates should be taken. 
Reducing the burden of disease is the primary objective of all immunization 
strategies. Assumptions of vaccine effectiveness are based on estimates dur-
ing the decision making process. Therefore basic epidemiologic data have to 
be compared with data (reduction of cases, hospitalizations and deaths) col-
lected after the implementation of national vaccine recommendations.24 Par-
ticularly in cases in which the time period between vaccination and desired 
effects is long, only the surveillance of changes in disease incidence, compli-
cations, sequalae and mortality provides data on real impact. For example, 
the influence of universal varicella vaccination on the incidence of zoster 
later in life is currently not known25. 
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The importance of immunosurveillance and consecutive opportunities to op-
timize national vaccination programs were recently outlined26: existing vac-
cine schedules are often based on historical developments rather than scien-
tific evidence. After surveillance of immunity (and re-infections leading to 
the disease) over a longer time period, it would often be necessary to alter a 
vaccination scheme. Effects on herd immunity might be different from those 
primarily expected and vaccination during pregnancy or perinatal time pe-
riods could become necessary if the protection of very young children is 
needed. Simultaneously other vaccines might be postponed if diseases are 
less frequent than at the time of introduction, having the advantage that 
fewer injections might be needed to be effective. Altering of vaccination 
schedules often fails, because this optimization can lead to (legal) problems 
due to the lack of studies performed with the new scheme.26  
Nevertheless these obstacles have to be overcome from a scientific as well as 
an economic point of view because of adaptations of immunization programs 
in changing environments and the increasing number of vaccines available26. 
As already discussed, data about adverse events following immunization 
might be incomplete at the time of vaccine introduction. Therefore the 
monitoring of safety performance of a vaccine should be obligatory.  In the 
past serious adverse events due to vaccination have occurred. Even deaths27 
or an increased incidence of neurodevelopmental disorders28 following im-
munization have been observed because of an increased dose of an addi-
tional agent or the added compound itself.  In the case of the rotavirus vac-
cination, discussions about possible changes in the incidence of intussuscep-
tions are still ongoing29. 
A lack of reporting of adverse events followed by immunization (AEFI) data 
as well as heterogeneity of case definitions and methods for data collection, 
analysis and presentation of AEFI was observed in a systematic review of 
published articles of prospective clinical trials of vaccines in humans30. Ef-
forts to improve AEFI reporting systems were carried out in the European 
research program for improved vaccine safety surveillance (EUSAFEVAC)31 
project between 2001 and 2003. As a result, tools for improved safety surveil-
lance of immunizations were made available by providing guidelines for 
standardized reporting of AEFI, using standardized case definitions or ex-
amples of active surveillance tailored at specific events signaled by routine 
passive surveillance. The ongoing VENICE10 project will also gather infor-
mation on the adverse events monitoring systems in the participating coun-
tries. 
Finally, in regards to safety monitoring issues, reliable independent safety 
boards are able to ensure optimal vaccine safety and would enhance public 
confidence in vaccines32. 
Global spread of virus strains that are not currently covered by a vaccine, 
challenges vaccine efficacy. This is commonly known in the case of influenza 
due to continuous antigenic variation, but might also occur in the case of 
other pathogens. Local distribution of specific antigen strains, in particular 
the emergence of strains that are not addressed by the currently used vac-
cine, may necessitate the replacement of a vaccine by a more effective one 
over time. For example, a change in serotype distribution recently has been 
observed after universal immunization of children against rotavirus33. Re-
placement diseases (increase in disease caused by serotypes not included in 
the vaccine) might emerge and have already been observed in the case of the 
Prevenar (7-valent pneumococcal conjugate) vaccine34 and in the case of 
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Haemophilus influencae type b conjugate vaccine35 after routine use. Age 
distribution of a disease is likely to change after vaccine introduction (e.g. 
drift of infections towards older groups of children after mumps vaccine in-
troduction in Poland36. Additionally all other expected positive and negative 
“side-effects” that have been outlined in step 4 have to be observed. 
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5 Limitations 
Challenges of vaccination strategies in special situations (e.g. immunosup-
pression, pregnancy or post-exposure) as well as those of therapeutic vac-
cines have not been addressed. Influences of organizational structures or 
health care systems on decision making were not analyzed. Therefore no best 
practice model that meets optimal conditions can be given.   
References given in the discussion were used as examples only and cannot 
cover all relevant aspects (e.g. indirect costs or vaccine safety issues). 
Due to the lack of comparable information, this study remains general and 
cannot provide specific advice or defined cut-off points. 
The proposed stepwise approach of decision making, the order as well as the 
criteria themselves, are suggestions and do not claim to be the correct and 
fixed procedures. This approach should rather be used by advisers and deci-
sion makers on vaccination policy as a basis for further discussion. In addi-
tion to the systematic literature search and the manual search of references 
and other sources, a Delphi process based on the results of this study will be 
carried out in spring 2008 to assess the completeness of criteria and the fea-
sibility of the step-wise approach. 
6 Conclusion 
Observing heterogeneous immunization programs and decisions in case of 
new vaccines on the one hand and the recent efforts of developing standard-
ized tools for decision making on the other hand emphasizes the demand for 
a higher degree of transparency in the vaccine implementation decision 
processes. 
This study confirms the basic assumption, that vaccine introduction is cur-
rently not based on a generalized rational decision making processes. The 
comparison of the five key documents led to a comprehensive framework, 
outlining as many issues to be taken into consideration as possible. A step-
wise approach could increase feasibility of decision aids. The lack of stan-
dardized measures, defined cut-off points and comparable weighing of in-
cluded criteria hinder rational decision making.  
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demand for 
transparency in 
deciding on new 
vaccines 
comprehensive 
framework with key 
issues for consideration 
as starting point  
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7 Annex 
Table 7-1: List of contacted persons who answered requests 
Amegah Thomas Dr., Amt der Steierma¨rkischen Landesregierung, Fachreferat 2, 
8011 Graz-Burg, Austria, +43316/877-3521, 
thomas.amegah@stmk.gv.at 
Appelgren Eva and Salmaso Stefania (VENICE), Centro Nazionale di 
Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), 
Istituto Superiore di Sanita`, Viale Regina Elena 299, 00161 Roma, 
Tel. +39 06 49904013, salmaso@iss.it , eva.appelgren@iss.it 
DiGuiseppi Carolyn, MD, MPH, PhD, Associate Professor, Department of 
Preventive Medicine and Biometrics, University of Colorado at 
Denver and Health Sciences Center, 4200 East Ninth Avenue, B119, 
Denver, CO 80262, Phone: 303-315-6850, 
Carolyn.DiGuiseppi@UCHSC.edu  
Erickson Lonny Ph.D, Research Scientist, Joint CHUM-MUHC Technology 
Assessment Unit,McGill University Health Centre, R4.14 Royal 
Victoria Hospital, 687 Pine Ave. W 
Montreal, Quebec H3A 1A1, lonny.erickson@muhc.mcgill.ca  
King Lisa (VENICE Epidemiologist), Levy-Bruhl Daniel Dr.(VENICE WP 4 
Leader), De´partement Maladies Infectieuses, Institut de Veille 
Sanitaire, 12 rue du Val d'Osne, 94415 Saint-Maurice cedex, France, 
+ 33 1 41 79 67 71, l.king@invs.sante.fr , d.levybruhl@invs.sante.fr 
Muchl Robert Dr., Bundesministerium fu¨r Gesundheit, Familie und Jugend, 
BMGFJ - III/A/1 (Infektionskrankheiten, Seuchenbeka¨mpfung, 
Krisenmanagement), Radetzkystrasse 2, A-1030 Wien, O¨sterreich,  
Tel: + 43 (0)1 711 00 4642, robert.muchl@bmgfj.gv.at 
Mutz Ingomar Univ. Prof. Dr., Vorsitzender der Impfkommission des Obersten 
Sanita¨tsrates in O¨sterreich, Schaldorferstrasse 2, 8641 St. Marein 
i.M., Austria, Tel +43 676 6278320, mutz.ingomar@speed.at 
Pammer Christoph, DSA MPH, wissenschaftlicher Mitarbeiter, 
Universita¨tslehrgang Public Health Graz, Universita¨tsplatz 4/3A, 
8010 Graz, Austria, Tel: +43 316 380 7772, 
christoph.pammer@meduni-graz.at 
Stoppacher Andreas Mag., Hauptverband d. o¨sterr. Sozialversicherungstra¨ger, 
Kundmanngasse 21, 1030 Wien, Austria, +43 1 71132 3111, 
andreas.stoppacher@hvb.sozvers.at 
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Table 7-2: Key questions (WHO 2000)  
7 key questions of the framework Issues to be addressed (Asian 
Vaccination Initiative assessment 
framework) 
Is the disease a public health 
problem? 
Is immunization the best control 
strategy fort his disease? 
Data Collection: (demographic, 
economic, political, health sector, 
immunization and vaccines legal 
status) Data characteristics and 
sources of necessary information are 
presented. 
Is the immunization program 
working well enough to add a 
vaccine? 
What will be the net impact of 
the vaccine? 
The Immunization Program: 
management(capacity), 
immunization delivery services, 
surveillance (of disease, coverage, 
adverse events), vaccine supply, 
logistic systems, safe injection 
practices, and communication 
 
Is the vaccine a good investment? 
How will the vaccine be funded? 
How will the addition of the new 
vaccine be implemented? 
Costs and financing requirements for 
the NIP: management, systems, 
budget, expenditure, sources 
 
Source: Mansoor O, Shin S, Maher C and the Immunization Focus, World Health 
Organization Regional Office for the Western Pacific. Assessing new vaccines 
for national immunization programmes- A framework to assist decision mak-
ers; available at http://whqlibdoc.who.int/hq/2000/9290611545.pdf, accessed 
on 1.2..2008 
Annex 
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Table 7-3: Criteria and key questions (Erickson 2005)  
category key question 
Burden of disease Does the burden of disease justify a control 
program? 
Vaccine characteristics Do the characteristics of the vaccine permit 
implementation of an effective and safe 
immunization program? 
Immunization strategy Is there an immunization strategy which allows 
goals of the control program as well as sanitary 
and operational objectives to be attained? 
Cost-effectiveness Is it possible to obtain funding for the program 
and are cost-effectiveness indices comparable to 
those of other health care interventions? 
Acceptability Does a high level of demand or acceptability 
exist for the immunization program? 
Feasibility Is program implementation feasible given 
existing resources? 
Ability to evaluate Can the various aspects of the program be 
evaluated? 
Research questions Have important research questions affecting 
implementation of the program been adequately 
addressed? 
Equity Is the program equitable in terms of accessibility 
of the vaccine for all target groups? 
Ethical considerations Have ethical concerns regarding implementation 
of the immunization program been adequately 
addressed? 
Legal considerations Have legal concerns regarding implementation 
of the immunization program been adequately 
addressed? 
Conformity of 
programs 
Does the planned program conform to those 
planned and implemented elsewhere (other 
regions, countries)? 
Political considerations Will the proposed program be free of 
controversy and/or produce some immediate 
political benefits? 
Source: Erickson LJ, De Wals P, Farand L. An analytical framework for immuniza-
tion programs in Canada. Vaccine. 2005 Mar 31;23(19):2470-6. 
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Figure 7-1: Key issues in the decision process (WHO 2005) 
Source: World Health Organization. Immunization, Vaccines and Biologicals, Intro-
duction Guideline- Adding a vaccine to a national immunization programme: 
decision and implementation. Available at  
http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.18.pdf , accessed on 
1.2.2008 
 
Annex 
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Figure 7-2: Considerations to adapt the national immunization program (Kimman 2006)  
Source: Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, 
de Melker HE. Developing a vaccination evaluation model to support evi-
dence-based decision making on national immunization programs. Vaccine. 
2006 May 29;24(22):4769-78. 
 

 LBI-HTA | 2008 51 
8 References 
                                                             
1 Kudjawu Y et al in behalf of the Venice working group. The current status of 
HPV and rotavirus vaccines in national immunisation schedules in the 
EU – preliminary results of a VENICE survey, Eurosurveillance weekly 
release, volume 12, issue 4, 26.4.2007 available at  
http://venice.cineca.org/Euroweekly_HPV_and_rotavirus_Apr_07.pdf, 
accessed on 1.2.2008 
2 Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, de 
Melker HE. Developing a vaccination evaluation model to support evi-
dence-based decision making on national immunization programs. Vac-
cine. 2006 May 29;24(22):4769-78. 
3 Erickson LJ, De Wals P, Farand L. An analytical framework for immunization 
programs in Canada. Vaccine. 2005 Mar 31;23(19):2470-6. 
4 Stratton KR, Durch JS, Lawrence S, Editors Committee to Study Priorities for 
Vaccine Development. Division of Health Promotion and Disease Pre-
ventionInstitute of Medicine, Vaccines for the 21st Century: A Tool for 
Decisionmaking. National Academies Press. ISBN: 978-0-309-05646-5, 
476 pages, 6 x 9, hardback (2000) 
5 Mansoor O, Shin S, Maher C and the Immunization Focus, World Health Or-
ganization Regional Office for the Western Pacific. Assessing new vac-
cines for national immunization programmes- A framework to assist de-
cision makers; available at  
http://whqlibdoc.who.int/hq/2000/9290611545.pdf, accessed on 1.2.2008 
6 World Health Organization. Immunization, Vaccines and Biologicals, Intro-
duction Guideline- Adding a vaccine to a national immunization pro-
gramme: decision and implementation. Available at 
http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.18.pdf , accessed on 
1.2.2008 
7 WHO Department of Immunization, Vaccines and Biologicals and UNICEF 
Programme Division, Health Section. Global Immunization Vision and 
Strategy (GIVS) for the period 2006-2015 available at 
http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.05.pdf , accessed on 
5.12.2007 
8 European Centre for Disease Prevention and Control (ECDC), Vaccines& Im-
munisation. Available at  
http://ecdc.europa.eu/Health_topics/VI/VI.html, accessed on 1.2.2008 
9 Surveillance Community Network for Vaccine Preventable Infectious Diseases 
(EUVAC.NET). Available at http://www.euvac.net/, accessed on 1.2.2008 
10 Vaccine European New Integrated Collaboration Effort (VENICE). Available 
at http://venice.cineca.org/, accessed on 1.2.2008 
11 WHO Immunization, Vaccines and Biologicals. Available at 
http://www.who.int/immunization/en/ , accessed on 1.2.2008 
12 WHO Immunization, Vaccines and Biologicals. Varicella. Available at 
http://www.who.int/immunization/policy/varicella.pdf, accessed on 
1.2.2008 
Rational Vaccination Policies - decision support 
 
52 LBI-HTA | 2008 
                                                                                                                                   
13 Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: com-
puter simulations of five new strategies. Vaccine; 2004 Aug 13. 22(23-24): 
3154-65. 
14 Bos JM, Rumke HC et al. Health economics of a hexavalent meningococcal 
outer-membrane vesicle vaccine in children: potential impact of intro-
duction in the Dutch vaccination program. Vaccine. 2001 Oct 12; 20(1-2): 
202-207. 
15 Deuson RR, Brodovicz KG et al. Economic analysis of a child vaccination pro-
ject among Asian Americans in Philadelphia, Pa. Arch Pediatr Adolesc 
Med. 2001 Aug; 155(8): 909-914 
16 Getsios D, Caro JJ et al. Instituting a routine varicella vaccination program in 
Canada: an economic evaluation. Pediatr Infect Dis J. 2002 Jun; 21(6): 
542-547. 
17 Ess SM, Schaad UB et al. Cost-effectiveness of a pneumococcal conjugate im-
munisation program for infants in Switzerland. Vaccine. 2003 Jul 4; 
21(23): 3273-3281. 
18 Taira AV, Neukermans CP et al. Evaluating human papillomavirus vaccina-
tion programs. Emerg Infect Dis. 2004 Nov; 10(11): 1915 
19 Harris A, Yong K, et al. An economic evaluation of universal infant vaccina-
tion against hepatitis B virus using a combination vaccine (Hib-HepB): a 
decision analytic approach to cost effectiveness. Aust N Z J Public 
Health. 2001 Jun; 25(3): 222-229. 
20 Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumo-
coccal infection in adults. Cochrane Database Syst Rev. 
2003;(4):CD000422. 
21 de Melker HE, van den Hof S et al. Evaluation of the national immunisation 
programme in the Netherlands: immunity to diphtheria, tetanus, polio-
myelitis, measles, mumps, rubella and Haemophilus influenzae type b. 
Vaccine. 2003 Jan 30; 21(7-8): 716-20. 
22 Eurosurveillance weekly release, volume 11, issue 5, 11.5.2006, available at  
http://www.eurosurveillance.org/ew/2006/060511.asp , accessed on 
1.2.2008 
23 Eurosurveillance weekly release, volume 12, issue 7, 26.7.2007, available at 
http://www.eurosurveillance.org/ew/2007/070726.asp, accessed on 
1.2.2008 
24 Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. 
Historical comparisons of morbidity and mortality for vaccine-
preventable diseases in the United States. JAMA. 2007 Nov 14;298(18): 
2155-63. 
25 Boot, H. J., H. E. de Melker, et al. "Assessing the introduction of universal 
varicella vaccination in the Netherlands." Vaccine. 2006 Sep 11; 24(37-
39): 6288-99. 
26 van der Zeijst BA, Dijkman MI, Luytjes W, van Alphen AJ, van den Dobbel-
steen GP. On the design of national vaccination programmes. Vaccine. 
2007 Apr 20;25(16):3143-5. 
 
 LBI-HTA | 2008 53 
                                                                                                                                   
27 Darwish A, Roth CE et al. (2002). Investigation into a cluster of infant deaths 
following immunization: evidence for methanol intoxication. Vaccine. 
2002 Oct 4; 20(29-30): 3585-9. 
28 Geier DA, Geier MR . An assessment of downward trends in neurodevelop-
mental disorders in the United States following removal of Thimerosal 
from childhood vaccines. Med Sci Monit. 2006 Jun;12(6):CR231-9.  
29 Davidson G, Elliott EJ et al. Preventing rotavirus gastroenteritis: do you have 
the facts? J Paediatr Child Health. 2007 Jul-Aug;43(7-8):564-7.  
30 Bonhoeffer J, Zumbrunn B, Heininger U. Reporting of vaccine safety data in 
publications: systematic review. Pharmacoepidemiol Drug Saf. 2005 
Feb;14(2):101-6. 
31 European research program for improved vaccine safety surveillance 
(EUSAFEVAC). available at http://www.smittskyddsinstitutet.se/in-
english/about-smi/international-cooperation/collaboration-within-the-
eu/eusafevac/, accessed on 1.2.2008 
32 Salmon DA, Moulton LH et al. Enhancing public confidence in vaccines 
through independent oversight of postlicensure vaccine safety. Am J Pub-
lic Health. 2004 Jun;94(6):947-50  
33 Montenegro FM, Correia JB et al. Anticipating rotavirus vaccines in Brazil: 
detection and molecular characterization of emerging rotavirus serotypes 
G8 and G9 among children with diarrhoea in Recife, Brazil. J Med Virol. 
2007 Mar;79(3):335-40. 
34 Center KJ. Prevenar vaccination: review of the global data, 2006. Vaccine. 2007 
Apr 20; 25(16): 3085-9. 
35 de Almeida AECC, de Filippis I et al. Occurrence of Haemophilus influenzae 
strains in three Brazilian states since the introduction of a conjugate 
Haemophilus influenzae type b vaccine. Braz J Med Biol Res. 2005 
May;38(5):777-81 
36 Janaszek-Seydlitz W, Bucholc B, et al. Mumps in Poland since 1990 to 2003; 
epidemiology and antibody prevalence. Vaccine. 2005 Apr 15;23(21): 
2711-6. 
